{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-246494","form_type":"8-K","ticker":"CLDI","cik":"0001855485","company_name":"Calidi Biotherapeutics, Inc.","filed_at":"2022-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.470375+00:00","generated_at":"2026-06-23T09:12:34.809646+00:00","sec_items":["1.01","5.03","2.03","5.02","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"FLAG shareholders approve extension to Dec 14; 18.9M shares redeemed, co-CEO appointed","bullets":["Stockholders approved extension of business combination deadline to Dec 14, 2022, with three additional 3-month extensions possible.","Redemption of 18,871,976 shares, leaving 4,128,024 shares outstanding; trust account now $41.6M.","Issued extension notes totaling $490,000 to sponsor and Metric to fund extension and working capital.","Appointed Thomas A. Vecchiolla as co-CEO alongside William J. Weber, effective Sept 15, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-246494","json":"https://secwatch.observer/filing/0001193125-22-246494.json","markdown":"https://secwatch.observer/filing/0001193125-22-246494.md","text":"https://secwatch.observer/filing/0001193125-22-246494.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1855485/000119312522246494/0001193125-22-246494-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1855485/000119312522246494/d361604d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T09:12:34.809646+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"072728f89f","claim":"Thomas A. Vecchiolla was appointed as co-Chief Executive Officer at Calidi Biotherapeutics, Inc..","evidence_excerpt":"Effective September 15, 2022, the Company’s board of directors appointed Thomas A. Vecchiolla as co-Chief Executive Officer to serve in such role with William J. Weber, who will also serve as co-Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1855485/000119312522246494/0001193125-22-246494-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"co-Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}